Pharma CEO silence is complicity in the destruction of U.S. science Why leaders of the U.S.’s biggest drug companies should use their influence to stop a ruinous proposal Office of Management and Budget Director Russell Vought has poured gas on the founda... See more
Three decades in biotech: Richard Pops on policy, drug pricing and leadership Alkermes CEO on how policy, economics shape drug development, from the IRA to MFN and beyond Richard Pops has lived the biotech roller coaster over three decades as CEO of Alker... See more
Mind the gap: Parker Institute’s Knudsen points to urgent need to fix translation Knudsen says Parker Institute’s model is replicable, and diagnostics is a good place to start Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes t... See more
Trump’s psychedelic order tests review norms Atypical policymaking process raises concerns about rigor, precedent and politicization of regulatory decisions President Donald Trump’s executive order on psychedelics could accelerate the path to market for a... See more
Makary’s embrace of ideology, conspiracies puts FDA at risk: A Perspective Because the FDA commissioner is making regulatory decisions, his views about scientific evidence are concerning FDA Commissioner Marty Makary’s endorsement of debunked conspiracy t... See more
